Status:

TERMINATED

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer

Lead Sponsor:

Tokyo University

Collaborating Sponsors:

Human Genome Center, Institute of Medical Science, University of Tokyo

Conditions:

Colorectal Cancer

Colon Cancer

Eligibility:

All Genders

20-85 years

Phase:

PHASE1

PHASE2

Brief Summary

The purpose of this study is to evaluate the safety and time to progression of HLA-A\*0201 restricted epitope peptides VEGFR1 and VEGFR2 emulsified with Montanide ISA 51 in combination with Tegafur/Ur...

Detailed Description

VEGF receptor 1 and 2 are essential targets to tumor angiogenesis, and we identified that peptides derived from these receptors significantly induce the effective tumor specific CTL response in vitro ...

Eligibility Criteria

Inclusion

  • Advanced or recurrent colorectal cancer
  • Resistant against chemotherapy including CPT-11, l-OHP、+/- 5-FU +/- bevacizumab or difficult to continue the chemotherapy due to intolerable side effect(s)
  • ECOG performance status 0-2
  • Life expectancy \> 3 months
  • HLA-A\*0201
  • Laboratory values as follows
  • 2000/mm3\<WBC\<15000/mm3
  • Platelet count\>100000/mm3
  • Bilirubin \< 3.0mg/dl
  • Asparate transaminase \< 150IU/L
  • Alanine transaminase \< 150IU/L
  • Creatinine \< 3.0mg/dl
  • Able to receive oral Tegafur/Uracil/Folinate therapy
  • Able and willing to give valid written informed consent

Exclusion

  • Pregnancy(woman of childbearing potential:Refusal or inability to use effective means of contraception)
  • Breastfeeding
  • Active or uncontrolled infection
  • Unhealed external wound
  • Concurrent treatment with steroids or immunosuppressing agent
  • Prior chemotherapy,radiation therapy, or immunotherapy within 4 weeks
  • Uncontrolled brain and/or intraspinal lesion(s)
  • History of allergy to Tegafur, Uracil, and/or Folinate
  • Decision of unsuitableness by principal investigator or physician-in-charge

Key Trial Info

Start Date :

May 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2009

Estimated Enrollment :

14 Patients enrolled

Trial Details

Trial ID

NCT00677612

Start Date

May 1 2008

End Date

March 1 2009

Last Update

December 29 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Institute of Medical Science, The University of Tokyo

Minato-ku, Tokyo, Japan, 108-8639